{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sukheja P"],"funding":["HHS | National Institutes of Health","NIAID NIH HHS"],"pagination":["e02022-16"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5312080"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["Active tuberculosis (TB) and latent <i>Mycobacterium tuberculosis</i> infection both require lengthy treatments to achieve durable cures. This problem has partly been attributable to the existence of nonreplicating <i>M. tuberculosis</i> \"persisters\" that are difficult to kill using conventional anti-TB treatments. Compounds that target the respiratory pathway have the potential to kill both replicating and persistent <i>M. tuberculosis</i> and shorten TB treatment, as this pathway is essential in both metabolic states. We developed a novel respiratory pathway-specific whole-cell screen to identify new respiration inhibitors. This screen identified the biphenyl amide GSK1733953A (DG70) as a likely respiration inhibitor. DG70 inhibited both clinical drug-susceptible and drug-resistant <i>M."],"journal":["mBio"],"pubmed_title":["A Novel Small-Molecule Inhibitor of the <i>Mycobacterium tuberculosis</i> Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells."],"pmcid":["PMC5312080"],"funding_grant_id":["U19 AI109713","R21 AI111647","R33 AI111647","4R33 AI111647"],"pubmed_authors":["Sukheja P","Husain S","Soteropoulos P","Singleton E","Li SG","Awasthi D","Kumar P","Russo R","Brukh R","Connell N","Perryman AL","Alland D","Shrestha R","Freundlich JS","Mittal N"],"additional_accession":[]},"is_claimable":false,"name":"A Novel Small-Molecule Inhibitor of the <i>Mycobacterium tuberculosis</i> Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells.","description":"Active tuberculosis (TB) and latent <i>Mycobacterium tuberculosis</i> infection both require lengthy treatments to achieve durable cures. This problem has partly been attributable to the existence of nonreplicating <i>M. tuberculosis</i> \"persisters\" that are difficult to kill using conventional anti-TB treatments. Compounds that target the respiratory pathway have the potential to kill both replicating and persistent <i>M. tuberculosis</i> and shorten TB treatment, as this pathway is essential in both metabolic states. We developed a novel respiratory pathway-specific whole-cell screen to identify new respiration inhibitors. This screen identified the biphenyl amide GSK1733953A (DG70) as a likely respiration inhibitor. DG70 inhibited both clinical drug-susceptible and drug-resistant <i>M.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Feb","modification":"2026-06-08T06:17:25.841Z","creation":"2019-03-27T02:36:40Z"},"accession":"S-EPMC5312080","cross_references":{"pubmed":["28196957"],"doi":["10.1128/mBio.02022-16"]}}